The role of fibrates in the prevention of cardiovascular disease-a pooled meta-analysis of long-term randomized placebo-controlled clinical trials

American Heart Journal

Volumn 154, Issue 5, 2007, Pages 943-953

  Saha, Sandeep Ajoy ^a   Kizhakepunnur, Lenney G ^a   Bahekar, Amol ^a   Arora, Rohit R ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PLACEBO;

ARTICLE; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; HEART INFARCTION; HUMAN; LONG TERM CARE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CLOFIBRIC ACID; FOLLOW-UP STUDIES; HUMANS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME;

EID: 35548955508     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.07.011     Document Type: Article

References (56)

1. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care. JAMA 288 (2002) 2998-3007
3. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
4. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo controlled trial. Lancet 364 (2004) 685-696
5. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
7. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
8. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336 (1997) 153-162
9. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
10. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Results of the low dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge?. Ital Heart J 1 (2000) 810-820
11. Serruys P.W., de Feyter P., Macaya C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 (2002) 3215-3222
12. Tobert J.A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2 (2003) 517-526
13. Aikawa M., and Libby P. Lipid lowering therapy in atherosclerosis. Semin Vasc Med 4 (2004) 357-366
14. Aikawa M. Effects of statin therapy on vascular dysfunction. Coron Artery Dis 15 (2004) 227-233
15. Bray G.A., and Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 29 (2006) 109-117
16. Birjmohun R.S., Hutten B.A., Kastelein J.J.P., et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds-a meta-analysis of randomized controlled trials. J Am Coll Cardiol 45 (2005) 185-197
17. Hokanson J.E., and Austin M.A. Plasma triglyceride level as a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
18. Watts G.F., and Dimmitt S.B. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 10 (1999) 561-574
19. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
20. Physicians of the Newcastle upon Tyne region. Trial of clofibrate, in the treatment of ischaemic heart disease. BMJ 4 (1971) 767-774
21. Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. BMJ 4 (1971) 775-784
22. Report of the Committee of Principal Investigators. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 2 (1980) 379-385
23. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
24. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., et al. PPAR alpha and PPAR gamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15 (1996) 5336-5348
25. Hertz R., and Bishara-Shieban J. Mode of action of peroxisome proliferators as hypolipidemic drugs, suppression of apolipoprotein C-III. J Biol Chem 270 (1995) 13470-13475
26. Schoonjans K., Watanabe M., and Suzuki H. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator responsive element in the C promoter. J Biol Chem 270 (1995) 19269-19276
27. Vu-Dac N., Schoonjans K., Kosykh V., et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator activated receptor. J Clin Invest 96 (1995) 741-750
28. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 354 (1999) 1896-1900
29. Verhagen A.P., de Vet H.C.W., de Bie R.A., et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51 (1998) 1235-1241
30. Rubins H.B., Robins S.J., Collins D., et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
31. Tenkanen L., Manttari M., Kovanen P.T., et al. Gemfibrozil in the treatment of dyslipidemia-an 18-year mortality follow-up of the Helsinki Heart Study. Arch Int Med 166 (2006) 743-748
32. Frick M.H., Syvanne M., Nieminen M.S., et al., for the Lopid Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL-C cholesterol. Circulation 96 (1997) 2137-2143
33. Ruotolo G., Ericsson C.G., Tettamanti C., et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the bezafibrate coronary atherosclerosis intervention trial (BECAIT). J Am Coll Cardiol 32 (1998) 1648-1656
34. Ericsson C.G., Hamsten A., Nilsson J., et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 (1996) 849-853
35. The BIP Study Group. Secondary prevention by raising HDL-C cholesterol and reducing triglycerides in patients with coronary artery disease-the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
36. Diabetes Atherosclerosis Intervention Study (DAIS) investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 357 (2001) 905-910
37. Meade T., Zuhrie R., Cook C., et al. Bezafibrate in men with lower extremity arterial disease: randomized controlled trial. BMJ 325 (2002) 1139-1143
38. The FIELD study investigators. Effects on long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 366 (2005) 1849-1861
39. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959) 719-748
40. Elkeles R.S., Diamond J.R., Poulter C., et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 21 (1998) 641-648
41. Studer M., Briel M., Leimenstoll B., et al. Effect of different antilipidemic agents and diets on mortality. Arch Int Med 165 (2005) 725-730
42. Cholesterol Treatment Trialists' (CTT) collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366 (2005) 1267-1278
43. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
44. Gervois P., Torra I.P., Fruchart J.C., and Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 38 (2000) 3-11
45. Chinetti G., Lestavel S., Bocher V., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 (2001) 53-58
46. Delerive P., Martin-Nizard F., Chinetti G., et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85 (1999) 394-402
47. Fruchart J.C., Duriez P., and Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10 (1999) 245-257
48. Marx N., Mackman N., Schonbeck U., et al. PPAR alpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 103 (2001) 213-219
49. Neve B.P., Corseaux D., Chinetti G., et al. PPAR alpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103 (2001) 207-212
50. Koskinen P., Manttari M., Manninen V., et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15 (1992) 820-825
51. Rubins H.B., Robins S.J., Collins D., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans' Affairs High-density lipoprotein Intervention Trial (VA-HIT). Arch Int Med 162 (2002) 2597-2604
52. Tenenbaum A., Motro M., Fisman E.Z., et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Int Med 165 (2005) 1154-1160
53. Keech A., Simes J., Barter P., et al., on behalf of the FIELD Management Committee. Correction to the FIELD study report. Lancet 368 (2006) 1415
54. Prueksaritanont T., Tang C., Qiu Y., et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30 (2002) 1280-1287
55. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 (2005) 120-122
56. No authors listed. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Available online at. http://www.accordtrial.org/public/index.cfm Accessed January 12, 2007